Scynexis' lead drug scores in vaginal yeast infection trial
Antifungal drug developer Scynexis, which burst into the zeitgeist as one of the sole US-based companies with a Candida auris therapy in human trials, on Thursday disclosed that the same experimental drug had hit the main goal in a late-stage trial in patients with vaginal yeast infections.
The oral drug, ibrexafungerp, was being tested in the 376-patient, placebo-controlled VANISH-303 trial. Patients enrolled had experienced an acute episode of vulvovaginal candidiasis (VVC), with signs and symptoms score of four or greater on a scale of zero to 18.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.